Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes

Key Findings

💊 CagriSema Beats Semaglutide Alone — By a Meaningful Margin

• A meta-analysis of 7 randomized trials (8,069 participants) found that CagriSema — a fixed-dose combo of semaglutide and a long-acting amylin analogue — produced about 7.6 kg more weight loss than semaglutide alone and nearly 9.25 kg more than the amylin component by itself.
• Side effects were mostly gastrointestinal and injection-site reactions, with no increase in serious adverse events versus comparators.

❤️ GLP-1 Drugs May Not Protect Hearts in People Without Prior Heart Disease

• A systematic review of 11 large trials (77,419 participants) found that GLP-1 drugs did not significantly reduce major cardiovascular events in people with type 2 diabetes who had no prior heart disease history — pooled hazard ratio 0.88, but the confidence interval crossed 1.
• Only about 26% of participants across included trials were in this 'primary prevention' category, meaning the trials weren't designed to answer this question in the first place.

🧠 Semaglutide Linked to Fewer Cognitive Symptoms in Psychiatric Patients

• A retrospective U.S. cohort study of 13,007 patients with psychiatric diagnoses found that semaglutide use was associated with reduced cognitive signs and symptoms compared to those not on the drug.
• The finding is observational and the population had existing psychiatric conditions, so confounding is a real concern — but the size of the cohort makes it worth watching.

😤 Ozempic Stigma Is Real — and Measurably Worse Than Bariatric Surgery Stigma

• An experiment with 297 participants found that a fictional person who lost weight using Ozempic was rated more negatively and assumed to be less healthy than someone who lost weight through diet and exercise alone.
• Notably, bariatric surgery did not produce the same stigma penalty — suggesting the 'easy way out' judgment is specifically attached to weight-loss drugs right now.

🏋️ Oral GLP-1 Drug Shows Long-Term Safety in Japanese Patients

• A phase 3 trial (ACHIEVE-J) evaluated orforglipron — a once-daily oral GLP-1 drug that requires no injection — as an add-on therapy in Japanese adults with type 2 diabetes, published in The Lancet Diabetes & Endocrinology.
• The trial focused on long-term safety in an East Asian population, a group with distinct metabolic characteristics that are often underrepresented in global drug trials.

🔬 A New Dual-Target Drug Outperforms GLP-1 Alone on Weight — Without the Muscle Concerns

• A phase 2 U.S. trial of mazdutide — which targets both glucagon and GLP-1 receptors — tested doses up to 16 mg weekly in adults with obesity but without type 2 diabetes, published in The Lancet Diabetes & Endocrinology.
• The glucagon receptor component is designed to boost energy expenditure, offering a mechanistically different path to weight loss compared to GLP-1 alone.